Abacavir

Main information

  • Trade name:
  • Abacavir 300 mg Film coated tablet
  • Dosage:
  • 300 mg
  • Pharmaceutical form:
  • Film coated tablet
  • Units in package:
  • Bottle, HDPE bottle with 38mm CRC cap and 1g silical gel bag (60 tablets), 60 tablets
  • Class:
  • Prescription
  • Prescription type:
  • Prescription
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug
  • Manufactured by:
  • Mylan Laboratories Limited

Documents

Localization

  • Available in:
  • Abacavir 300 mg Film coated tablet
    New Zealand
  • Language:
  • English

Therapeutic information

  • Therapeutic indications:
  • Abacavir tablets are indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults and children.

Other information

Status

  • Source:
  • Medsafe - Medicines Safety Authority - New Zealand
  • Authorization number:
  • 12764
  • Authorization date:
  • 27-07-2006
  • Last update:
  • 27-09-2017

11-12-2018

Ziagen (ViiV Healthcare BV)

Ziagen (ViiV Healthcare BV)

Ziagen (Active substance: abacavir sulfate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)8685 of Tue, 11 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/252/T/104

Europe -DG Health and Food Safety

18-10-2018

Kivexa (ViiV Healthcare BV)

Kivexa (ViiV Healthcare BV)

Kivexa (Active substance: abacavir / Lamivudine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6924 of Thu, 18 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/000581/T/0076

Europe -DG Health and Food Safety

2-10-2018

Trizivir (ViiV Healthcare BV)

Trizivir (ViiV Healthcare BV)

Trizivir (Active substance: abacavir, lamivudine, zidovudine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6483 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/338/T/108

Europe -DG Health and Food Safety

15-5-2018

Lonquex (UAB Sicor Biotech)

Lonquex (UAB Sicor Biotech)

Lonquex (Active substance: lipegfilgrastim) - Centralised - Renewal - Commission Decision (2018)3009 of Tue, 15 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2556/R/39

Europe -DG Health and Food Safety